A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer.

Trial Information

A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer.

Inclusion Criteria:

- Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse
large cell non-Hodgkin's lymphoma, histologically or cytologically proven at
diagnosis which is refractory to or intolerant of established therapy know to provide
clinical benefit for their condition; tumors must express Rb

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.